FIGURE 4. 17-HDHA and AT-RvD1 adjuvant-enhanced efficacy of P6 vaccination augments bacterial clearance in the lungs of SHS-exposed mice.

Mice exposed to SHS for 8 wks were either (A) untreated or (B) treated with AT-RvD1 for 8 wks prior to vaccination with P6 ± SPM adjuvant AT-RvD1 or 17-HDHA. All mice received acute intratracheal NTHI challenge 8 wks after the start of vaccination. Pulmonary bacterial burden in SHS-exposed, vaccinated mice was measured at 4 and 24 h following acute infection and data expressed as (C) total number of CFUs recovered. All treatment groups were assayed at the same time, and data represent results generated from a single experiment using a total of n=24 mice at each time point. Data from individual mice are shown, the line represents geometric mean ± 95% C.I. Statistical significance was determined as described in the methods section (overall p<0.0001 comparing SHS, P6+vehicle group vs all treatment groups with Tukey’s posttest for multiple comparisons at 4 and 24 h).